9. Merck (MRK) is a global pharmaceutical company. It is scheduled to report fourth-quarter results today.
12-Month Profit Growth: -2.1%
12-Month Stock Performance: -15%
3-Year Annualized Sales Growth: 22%
3-Year Annualized Profit Growth: 14%
3-Year Annualized Stock Performance: -10%
Current Dividend Yield: 4.5%
3-Year Annualized Dividend Growth: 0%
5-Year Annualized Dividend Growth: 0%
Bullish Scenario: Credit Suisse rates Merck "outperform", expecting its stock to climb 30% to $44. Bearish Scenario: Jefferies ranks Merck "hold", predicting that its stock will inch up 2% to $34.50.